BACKGROUND: Studies of chromosomal rearrangements and fusion transcripts have elucidated mechanisms of tumorigenesis and led to targeted cancer therapies. This study was aimed at identifying novel fusion transcripts in esophageal adenocarcinoma (EAC). METHODS: To identify new fusion transcripts associated with EAC, targeted RNA sequencing and polymerase chain reaction (PCR) verification were performed in 40 EACs and matched nonmalignant specimens from the same patients. Genomic PCR and Sanger sequencing were performed to find the breakpoint of fusion genes. RESULTS: Five novel in-frame fusion transcripts were identified and verified in 40 EACs and in a validation cohort of 15 additional EACs (55 patients in all): fibroblast growth factor receptor 2 (FGFR2)-GRB2-associated binding protein 2 (GAB2) in 2 of 55 or 3.6%, Niemann-Pick C1 (NPC1)-maternal embryonic leucine zipper kinase (MELK) in 2 of 55 or 3.6%, ubiquitin-specific peptidase 54 (USP54)-calcium/calmodulin dependent protein kinase II g (CAMK2G) in 2 of 55 or 3.6%, megakaryoblastic leukemia (translocation) 1 (MKL1)-fibulin 1 (FBLN1) in 1 of 55 or 1.8%, and CCR4-NOT transcription complex subunit 2 (CNOT2)-chromosome 12 open reading frame 49 (C12orf49) in 1 of 55 or 1.8%. A genomic analysis indicated that NPC1-MELK arose from a complex interchromosomal translocation event involving chromosomes 18, 3, and 9 with 3 rearrangement points, and this was consistent with chromoplexy. CONCLUSIONS: These data indicate that fusion transcripts occur at a stable frequency in EAC. Furthermore, our results indicate that chromoplexy is an underlying mechanism that generates fusion transcripts in EAC. These and other fusion transcripts merit further study as diagnostic markers and potential therapeutic targets in EAC.
INTRODUCTION
Esophageal cancer is the eighth most common cancer and the sixth leading cause of cancer-related death in the world. 1 Esophageal cancer has 2 main histological subtypes: squamous cell carcinoma and adenocarcinoma. 2 Over the past 30 years, the incidence of esophageal adenocarcinoma (EAC) has risen approximately 7-fold in the United States. 3 EAC is now the predominant subtype of esophageal cancer in the United States. 1 Although the 5-year survival rate for EAC patients has remained below 25%, largely because of late diagnosis, 4 Barrett's esophagus (BE), a premalignant lesion, is the most significant risk factor for developing EAC. 5 It has been reported that 5% of BE cases will ultimately progress into EAC. 6 The mechanisms underlying malignant transformation in BE are poorly understood, but an improved understanding of these mechanisms could lead to improved survival by providing biomarkers for early detection as well as therapeutic target strategies.
Molecular genetic studies of EAC have revealed that mutations in key cancer-causing genes such as TP53, CDKN2A, and SMAD4 are involved in the genesis and advancement of EAC. [7] [8] [9] In addition, chromosomal rearrangements may also play a critical role in EAC development. Recently, whole-genome sequencing of EAC has confirmed that chromosomal rearrangements occur in EAC. 9, 10 Chromosomal rearrangements can exert their effects through 1 of 2 alternative mechanisms: 1) dysregulation, usually resulting in the overexpression of a normal gene at 1 of the breakpoints, or 2) the creation of a fusion protein. 11 There is extensive evidence showing that fusion proteins participate in carcinogenesis. One classic example is the fusion gene BCR-ABL, which occurs in patients with chronic myelogenous leukemia, acute lymphocytic leukemia, and acute myelogenous leukemia. 11 Notably, fusion genes can also serve as diagnostic markers and therapeutic targets, as shown for fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil containing protein 3 (TACC3) fusions in glioblastoma and echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions in lung cancer. 12, 13 Although chromosomal rearrangements have been reported in EAC, no driver events caused by fusion genes have yet been described in this malignancy. Recently, Blum et al 14 identified ribosomal protein S6 kinase B1 (RPS6KB1)-vacuole membrane protein 1 (VMP1) as a fusion transcript that modulates autophagy in EAC. With the exception of this single study, however, there have been no comprehensive reports of fusion transcripts in EAC. The identification of fusion events is essential for enhancing our understanding of EAC and for promoting the development of early detection biomarkers as well as targeted therapeutic strategies to improve the outcomes of this disease, as discussed previously.
In the current report, we identified and characterized 5 novel fusion transcripts with next-generation RNA sequencing in 40 paired EAC specimens and nonmalignant specimens. In addition, a genomic analysis revealed that 1 fusion transcript, Niemann-Pick C1 (NPC1)-maternal embryonic leucine zipper kinase (MELK), resulted from a complex structural rearrangement event involving 3 chromosomes, which is typical of the recently proposed phenomenon known as chromoplexy. 15 
MATERIALS AND METHODS

Patients and Samples
EAC specimens and adjacent nonmalignant tissues from 40 patients were obtained from the Johns Hopkins University and the University of Maryland Hospitals. An additional independent cohort of 15 patients from the Johns Hopkins University and the University of Maryland Hospitals was also studied. All patients provided written informed consent under protocols approved by the institutional review boards at the Johns Hopkins University or the University of Maryland School of Medicine. All tissues were pathologically confirmed to be EAC.
Cell Lines
Three human EAC-derived cell lines (OE33, SKGT4, and Flo-1), 5 human gastric cancer-derived cell lines (MKN28, KATOIII, AGS, NCIN87, and SNU1), immortalized normal esophageal epithelial cells (Het1A), and immortalized normal gastric epithelial cells (HFE145) were also analyzed in this study. The cell lines KATOIII, AGS, NCIN87, SNU1, and Het1A were purchased from the American Type Culture Collection (Manassas, Virginia). MKN28 was a gift from Dr. Gen Tamura (Department of Pathology, Yamagata University School of Medicine, Yamagata, Japan), and the HFE145 cells were a gift from Dr. Duane Smoot (Division of Gastroenterology, Howard University College of Medicine, Washington, DC). OE33, SKGT4, and Flo-1 were purchased from the European Collection of Cell Culture (Porton Down, United Kingdom), Sigma Chemical (St. Louis, Missouri), and ScienCell Research Laboratories (Carlsbad, California), respectively.
Complementary DNA (cDNA) Library Preparation and Sequencing
The total RNA from 40 paired EAC specimens was extracted with the RNeasy Mini Kit (Qiagen, Gaithersburg, Md.). The total RNA was converted into a cDNA library and was then selectively enriched for 1385 cancerassociated genes with the TruSight RNA Pan-Cancer Panel Kit according to the manufacturer's instructions (Illumina). The TruSight RNA Pan-Cancer Panel is a targeted sequencing strategy that enables the measurement of gene expression, variant calling, and fusion detection of cancer-related genes with a limited sample quantity. This approach has the ability to detect fusions not only between any of the 1385 genes in the panel but also between any of these genes and other novel fusion partners (eg, FGFR1-X fusions, where X is any possible gene). All RNA sequencing was performed on MiSeq instruments with V3 reagents according to the manufacturer's instructions (Illumina).
Bioinformatics Analysis
We used the BaseSpace RNA-Seq Alignment App (ver- (including Bowtie, Bowtie2, and TopHat). The Homo sapiens University of California Santa Cruz hg19 reference genome was used for alignment. Input reads were filtered out according to the following conditions: 1) reads that failed base-calling quality checks, 2) reads marked as polymerase chain reaction (PCR) duplicates, 3) paired-end reads not marked as a proper pair, and 4) reads with a mapping quality < 20. STAR is a fast RNA sequencing read mapper with support for splice junction and fusion read detection. STAR aligns reads by finding the Maximal Mappable Prefix hits between reads (or read pairs) and the reference genome. Manta was used in combination with STAR to identify fusion transcripts. Fusion transcripts were filtered on the basis of the following criteria: 1) read counts across fusion and alignment qualities, 2) genomewide realignment of fusion contigs to filter candidates that could be explained by a local alignment elsewhere in the genome, and 3) length of coverage around breakpoints (indicating the presence of stable fusion transcripts). Only high-confidence candidate fusion transcripts passing these filters were selected for downstream analysis.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
The total RNA from tissues or cell lines was extracted with the RNeasy Mini Kit (Qiagen). The total RNA (0.5 lg) was reverse-transcribed into cDNA with the ThermoScript RT-PCR System Kit (Invitrogen, Grand Island, NY) according to the manufacturer's instructions. The resulting cDNA was used as a template for PCR amplification with the following primers spanning fusion transcript junctions:
Ubiquitin-specific peptidase 54 (USP54 PCR amplification was performed with Taq DNA polymerase (Invitrogen). PCR products were analyzed with agarose gel electrophoresis.
Genomic DNA PCR
To precisely locate the DNA breakpoints resulting in the fusion transcript NPC1-MELK, genomic DNA PCR was performed. DNA was extracted from frozen tissues containing the NPC1-MELK transcript with the DNeasy Blood and Tissue Kit (Qiagen). The DNA (0.1 lg) was used as a template for PCR amplification with Platinum Taq DNA polymerase (Invitrogen). The primers were as follows: 5 0 -ATTCCTGCCCATGTTCCTTT-3 0 (forward primer) and 5 0 -CCCAAAATCTGACTGTGTT TG-3 0 (reverse primer). The PCR products were analyzed with agarose gel electrophoresis.
TOPO Cloning and Sanger Sequencing
The amplified products of RT-PCR and genomic PCR were cloned into the pCR 4-TOPO TA vector and transformed into Escherichia coli according to the manufacturer's instructions (Thermo-Fisher Scientific). Then, the vector was extracted with the Plasmid Mini Kit (Qiagen) and was sequenced via Sanger sequencing according to the manufacturer's instructions.
RESULTS
RNA Sequencing of 40 EACs and Matched Normal Specimens
Forty freshly frozen EAC specimens and their matched nonmalignant tissues were collected for targeted RNA sequencing, as described previously. The demography of the patients is shown in Supporting Table 1 (see online supporting information). The mean read count was 3,543,321, and the mean ratio of aligned reads was 96%. To identify fusion transcripts, we analyzed paired-end sequencing reads with Manta according to the strategy mentioned previously.
Identification and Validation of Fusion Transcripts
After the Manta workflow, we identified 6 novel highconfidence fusion transcripts in the initial 40-patient cohort.
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These 6 fusion transcripts included FGFR2-GAB2 (3 of 40), NPC1-MELK (2 of 40), USP54-CAMK2G (2 of 40), MKL1-FBLN1 (2 of 40), CNOT2-C12orf49 (1 of 40), and MEGF9-GSN (1 of 40). To validate the fusion transcripts found by RNA sequencing, PCR was performed with primers spanning the junctions of each fusion transcript. Five of these 6 identified fusion transcripts were validated by PCR (Fig. 1C-G) ; the exception was MEGF9-GSN. In addition, 1 of the 3 samples showing FGFR2-GAB2 and 1 of the 2 samples showing MKL1-FBLN1 were not validated by RT-PCR, and this suggested that these findings were due to false-positive RNA sequencing reads.
Supporting Table 2 (see online supporting information) shows read counts that support fusion transcripts and the RNA sequences in those conjunctions. These read maps show that FGFR2-GAB2 and NPC1-MELK were detected at a high sequencing depth (Fig. 1A,B) . Next, we used Sanger sequencing to sequence the junction regions amplified by PCR, which yielded 100% concordance between RNA sequencing and Sanger sequencing (Fig. 1C-G) . The sequencing of these junction regions demonstrated that exon 19 of FGFR2 was fused to exon 2 of GAB2, exon 20 of NPC1 was fused to exon 18 of MELK, exon 2 of MKL1 was fused to exon 17 of FBLN1, exon 14 of USP54 was fused to exon 4 of CAMK2G, and exon 15 of CNOT2 was fused to exon 4 of C12orf19.
To confirm the recurrent nature and frequencies of these 5 fusions, we screened 15 additional independent paired EAC samples, 3 EAC cell lines (OE33, SKGT4, and Flo-1), 1 immortalized normal esophageal epithelial cell line (Het1a), 5 gastric cancer cell lines (MKN28, KATOIII, AGS, NCIN87, and SNU1), and 1 immortalized normal gastric epithelial cell line (HFE145). However, none of these 5 fusion transcripts were observed in this additional cohort or in any of the studied cancer lines ( Fig. 1C ; data from cell lines not shown).
FGFR2-GAB2 and NPC1-MELK arose from the fusion of sequences located on different chromosomes. USP54-CAMK2G, MKL1-FBLN1, and CNOT2-C12orf49 arose from the fusion of sequences located on the same chromosome. The distances between the 2 partners of fusion transcripts located in the same chromosome were 331,209 to 46,415,586 base pairs (331,209 in USP54-CAMK2G, 5,136,964 in MKL1-FBLN1, and 46,415,596 in CNOT2-C12orf49; Table 1 ). Given the large distances between the respective partners of these fusion genes, we speculate that these fusion genes more likely resulted from chromosomal rearrangement than transcriptional read-through. Given that the 2 partners of NPC1-MELK and FGFR2-GAB2 were located on different chromosomes, we prioritized NPC1-MELK and FGFR2-GAB2 for further studies. . 16, 17 In the current study, 2 of the 55 EAC patients, EAC3869 and EAC5061, were validated by PCR to be harboring the FGFR2-GAB2 fusion transcript (Fig. 1C,D) . RNA sequencing of the junction region showed that exon 19 of FGFR2 was fused to exon 2 of GAB2 in frame ( Fig. 2A) . In the normal genome, FGFR2 and GAB2 map to chromosomes 10q26 and 11q14.1, respectively. Given the high frequency of fusion events involving FGFR2 in other cancer types, we conclude that the FGFR2-GAB2 fusion transcript reported here likely resulted from a genomic DNA rearrangement. On the basis of the sequencing of this FGFR2-GAB2 fusion transcript, the putative structure of the FGFR2-GAB2 fusion protein is displayed in Figure 2B . Most of FGFR2 and a portion of GAB2 were retained in this putative fusion protein.
Complex Chromosome Translocation Underlying the NPC1-MELK Fusion Transcript
To characterize the genomic translocation giving rise to the NPC1-MELK fusion transcript, we extracted DNA from the 2 EAC specimens (EAC3253 and EAC3274) containing this fusion, and then we PCR-amplified the junction containing the breakpoint with genomic DNA PCR and sequenced this product with Sanger sequencing (Fig. 3B) . Interestingly, the sequencing results revealed that 2 additional DNA fragments were inserted into the junction region. One fragment consisted of partial intron 3 and partial exon 4 of MCM2 (located on chromosome 3), whereas the other fragment comprised a partial antisense isoform of MELK (Fig. 3C) . Both of these intronic fragments were apparently removed, and the end of exon 20 of NPC1 was apparently spliced to the beginning of exon 18 of MELK during the process of RNA splicing (Fig. 3A) . Therefore, we concluded that the NPC1-MELK fusion transcript was derived from complex interand intrachromosomal rearrangements consisting of 3 fusion points involving chromosomes 18, 3, and 9, and this was consistent with the recently described phenomenon of chromoplexy. 15 In addition, the 2 samples harboring NPC1-MELK (EAC3253-T and EAC3274-T) also contained other fusion transcripts, as shown in Figure 1C , and this suggested that EAC3253-T and EAC3274-T were subject to complex chromosomal rearrangements having at least 3 fusion points involving more than a single chromosome. 18 In addition, both patients had advanced tumors (T4N2M0 and T3aN1M0, respectively). Finally, both patients had received preoperative adjuvant chemoradiotherapy and had obtained a partial response to therapy.
DISCUSSION
Chromosomal rearrangements are a hallmark of carcinogenesis in many human tumor types. Recently, several large cohort studies based on next-generation sequencing have reported high-frequency chromosomal rearrangements in EAC. 9, 10 However, these studies did not explore the effects of these rearrangements and consequent fusion transcripts on the progression of EAC. In the current study, we identified 5 novel fusion transcripts in EAC: FGFR2-GAB2, NPC1-MELK, USP54-CAMK2G, MKL1-FBLN1, and CNOT2-C12orf49. In addition, our data reveal that complex genomic rearrangements, typical of the recently described concept of chromoplexy, 15 gave rise to the NPC1-MELK fusion transcript. FGFR2 fusion events have been recently described in multiple cancer types, including glioblastoma, iCCA, and bladder, lung, breast, and prostate cancers. Multiple partner genes were identified in these fusions, including PPHLN1, BICC1, AFF3, CASP7, KIAA1967, OFD1, CCDC6, TXLN1, KCTD1, and ACSL5. 16, 17, 19, 20 FGFR2 fusions are, in fact, the most recurrent chromosomal rearrangements in human tumors. It was reported that FGFR2-PPHLN1 occurred in 45% of iCCA cases and that FGFR2-BICC1 occurred in 38% of iCCA cases. 16 However, the FGFR2-GAB2 fusion in this study, 
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Cancer October 15, 2017 being detected in only 2 of 55 patients with EAC (3.6%), was a low-frequency event, and this suggests that different cancer types may be unique in this respect. In addition, we also tested these 5 fusion genes in gastric cancer cell lines, where, however, no fusion gene was found. Whether these fusion genes occur in other tumor types is still unknown, and this is worthy of further study. Because FGFR2 is a frequent target of genomic rearrangement in many human tumors, it will be quite worthwhile to search for FGFR2-GAB2 in other tumor types. In addition, exploring these fusion genes in other data sets is a good strategy for discovering whether these fusion transcripts are recurrent in EACs or other tumor types at other clinical centers. We hope to collaborate with bioinformatics specialists to tackle this undertaking in future studies.
Interestingly, 9 of 10 FGFR2 fusions reported to date involve the same breakpoint (exon 19) and contain the principal functional domain of wild-type FGFR2. 16, 17 It has been reported that most of the FGFR fusion partners contribute oligomerization domains to induce the activation of FGFR kinase. 17 For example, Sia et al 16 verified that the phosphorylation level of the FGFR2-PPHLN1 fusion protein and the activation of downstream mitogen-activated protein kinase ERK1/2 increased in comparison with wild-type FGFR2. In the current study, we also demonstrated that exons 1 to 19 of FGFR2 were present in the 5 0 end of our fusion transcript. Thus, FGFR2-GAB2 has a functional structure analogous to FGFR2 kinase fusions described in other cancer types, and this suggests a shared mechanism involving the kinase. Although the precise function of FGFR2-GAB2 in EAC is still unknown, this hypothesis merits further study.
According to the findings of FGFR2 fusion genes in previous studies as well as our own, the breakpoint location of FGFR2 rearrangements is stable in intron 19. However, this finding does not necessarily mean that other genes involved in fusions also have stable breakpoints. Actually, even the same fusion gene may have many isoforms and different breakpoints. For example, FGFR3-TACC3 is a recurrent fusion gene found in nasopharyngeal carcinoma. It has been reported that different isoforms of FGFR3-TACC3 occur, such as a gene fusion between exon 18 of FGFR3 and exon 6 or 14 of TACC3 or between exon 19 of FGFR3 and exon 11 of TACC3. 21 In addition, it has been reported that a loss of the 3 0 untranslated region, which contains targets of microRNAs, results in FGFR3 fusion transcript overexpression. 22 In agreement with these observations, the 5 0 FGFR2 portion of FGFR2-GAB2 in our study also lost the 3 0 untranslated region. This finding suggests that upregulated expression of FGFR2-GAB2 in EAC may be due, at least in part, to escape from microRNA regulation. In addition, drug targeting of FGFR2 fusions has proven to be an effective therapeutic approach in certain cancers. For example, Sia et al 16 proved that HUCCT1 cells overexpressing the FGFR2-PPHLN1 fusion protein showed enhanced sensitivity to the chemotherapeutic agent BGJ398 in comparison with the parental cell line transfected with an empty vector. Thus, FGFR2-GAB2 may represent a potential target of FGFR2 inhibitors in EAC patients; this possibility merits further study.
With the increasing application of whole-genome and whole-transcriptome sequencing approaches, it has become evident that chromosomal rearrangements are more frequent and complex than previously recognized. 23, 24 Complex chromosomal rearrangements that contain at least 3 genomic breakpoints involving more than a single chromosome have been detected in a broad spectrum of tumors, including prostate cancer, bone cancer, lung cancer, and medulloblastoma. 18, 25 For example, Baca et al 15 reported that 88% of prostate tumors contained chains of 5 or more rearrangements. It is difficult to explain this phenomenon with the classic view that chromosomal rearrangements are caused by a gradual accumulation of DNA damage. Recently, several new mechanisms, such as chromothripsis and chromoplexy, have been proposed to account for complex chromosomal rearrangements. According to these and other new mechanisms, complex rearrangements can be derived from a single catastrophic event rather than gradually. 26 The distinction between these 2 mechanisms is that genomic breakpoints in chromothripsis, usually numbering in the hundreds, are clustered within specific regions of 1 or 2 chromosomes, whereas those in chromoplexy are unclustered, usually numbering in the tens and involving multiple chromosomes. 23 Complex chromosomal rearrangements similar to chromothripsis were found in 44 of 123 EACs. 10 In the current study, we detected multiple fusion transcripts in 2 of 55 EAC patients (NPC1-MELK, USP54-CAMK2G, MKL1-FBLN1, and CNOT2-C12orf49 in EAC3253 and NPC1-MELK and USP54-CAMK2G in EAC3274). In addition, 3 fusion points were detected in the junction region of fusion transcript NPC1-MELK, which involved complex inter-and intrachromosomal rearrangements. The relatively low frequency of complex chromosomal rearrangements detected in our study may have been due to the targeted RNA sequencing method we used, which covers only 1385 tumor-related genes rather than the whole transcriptome. The NPC1-MELK fusion transcript, involving 3 breakpoints and 3 chromosomes in total, is consistent with chromoplexy. We speculate that NPC1-MELK, USP54-CAMK2G, MKL1-FBLN1, and CNOT2-C12orf49 may constitute components of this chromoplexy. Chromoplexy accounts for several known fusion genes. For example, the transmembrane protease serine 2 (TMPRSS2)-ETS-related gene (ERG) fusion, first found by Tomlins et al in 2005, 27 is a high-frequency recurrent fusion gene in prostate cancer. Baca et al 15 demonstrated that TMPRSS2-ERG is often found as part of chromoplexy in prostate cancer. 23 Taken together, our and others' findings suggest that chromoplexy may be an underlying mechanism causing complex fusion events in EAC. Next-generation DNA sequencing will be an efficient method for identifying chromoplexy in additional EACs and other types of tumors.
In addition, both chromoplexic tumors were at advanced stages. Interestingly, both patients with chromoplexy also had favorable responses to chemoradiotherapy. Although this sample size is too small to statistically analyze, these findings suggest that the involvement of chromoplexy in cancer progression and chemoradiosensitivity and the functional effects of fusion transcripts merit further research.
Cancer October 15, 2017 In conclusion, we discovered and validated 5 novel fusion transcripts in EAC. Chromoplexy may underlie complex chromosomal rearrangements that produce fusion genes in EAC. These fusion transcripts and this mechanism merit further study as potential diagnostic markers and therapeutic targets in EAC.
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